

Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/ collaboration on ACTIV activities?

Hi Francis

We certainly enjoy taking part in ACTIV

I will check if we did get our drugs on the lists below

(b) (4)

I will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats that is less advanced or a refined format of our most advanced in the master protocol etc

If we can agree about shared key endpoints , we can include that cross all studies Whether master protocol or more advanced sponsor trials which helps comparison

Happy to discuss w you and welcome your advice
Mikael

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President,
Worldwide Research, Development and Medical
Pfizer Inc.
235 East 42nd Street
New York, NY 10017

On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E] <[REDACTED]> (b) (6) wrote:
Mats

Hi Mikael,

Thanks for your note and this update on exciting progress on several fronts. ACTIV is moving forward with gratifying speed and commitment. With regard to vaccines, tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase II/III trial with adaptive design, multiple arms, and a shared placebo arm, aiming to launch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, and JnJ vaccines are likely to be included – might Pfizer also join?